Bristol-Myers Squibb Compnay

Viiv Healthcare UK (No.5) Limited

Viiv Healthcare UK Limited

Michael A Walker

B Narasimhulu Naidu

Margaret E Sorenson

Manoj Patel

Jacques Banville

Yasutsugu Ueda

Roger Remillard

Kevin M Peese

John D Matiskella

Timothy P Connolly

Francis Beaulieu

Carl Ouellet

Serge Plamondon

John F Kadow

Chen Li

Zhizhen Barbara Zheng

Nicholas A Meanwell

Mark R Krystal

David R Langley

Annapurna Pendri

Stanley V D'Andrea

Zhongyu Wang

Barry L Johnson

Hatice Belgin Gulgeze

Timothy D Johnson

Tao Wang

Zhongxing Zhang

Zhiwei Yin

Katharine A Grant-Young

Martin D Eastgate

Oak K Kim

Yunhui Zhang

Michael S Bowsher

Bin Zheng

Ke Chen

Donald Thomas Corson

Francisco Gonzalez-Bobes

Gilles Bouthillier

Ira B Dicker

Rongti Li

Jonathan R Weiss

Ting T Yin

Narasimhulu B Naidu

Zhuping Ma

Jacque Banville

Yasutsuga Ueda

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. 

Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for making and using these compounds in the treatment of HIV infection. 

Inhibitors of human immunodeficiency virus replication

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

HIV integrase inhibitors

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor

The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV 

Bicyclic heterocycles as HIV integrase inhibitors

The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

Growing community of inventors

Durham, CT, United States of America

Michael A Walker